TY - JOUR
T1 - Cyclic somatostatin analogues as potent antagonists at μ-, but not δ- and κ-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the brain
AU - Mulder, Arie H.
AU - Wardeh, George
AU - Hogenboom, François
AU - Kazmierski, Wieslaw
AU - Hruby, Victor J.
AU - Schoffelmeer, Anton N.M.
PY - 1991/11/19
Y1 - 1991/11/19
N2 - The opioid receptor antagonist properties of four conformaiionally constrained cyclic octapeptidc analogues of somatostatin were investigated using in vitro functional paradigms of μ-, δ- and κ-opioid receptors in the rat brain. The analogues examined were D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP), D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pcn-Thr-NH2 (CTAP), D-Tic-CTOP (TCTOP) and D-Tic-CTAP (TCTAP). Activation of μ-receptors by the enkephalin analogue Tyr-D-Ala-Gly-(NMc)Phc-Gly-ol (DAGO) inhibited the (electrically evoked) release of [3H]noradrenalinc (NA) from superfused cortical slices and this inhibitory effect was antagonized in a competitive fashion by all of the octapeptides tested (pA2 values: CTOP and CTAP 7.9-8.0, TCTOP and TCTAP 8.7-8.8). Selective activation of κ-opioid receptors by the cyclohcxylbenzeneacctamidc U69593 (0.02 μM) inhibited (by 40-45%) the release of [3H]dopamine (DA) from striatal slices, whereas selective activation of δ-opioid receptors by [D-Scr2O-t-butyl),Leu5]enkephalyl-Thr6 (DSTBULET; 0.1 μM) caused an inhibition (by 38-46%) of striatal [14C]acctylcholine (ACh) release. However, these inhibitory effects were not affected by any of the octapeptides in concentrations that caused full antagonism of the inhibitory effect (55-65%) of 0.1 μM DAGO on cortical [3H]NA release. Thus, the cyclic octapcptide somatostatin analogues CTOP, CTAP, TCTOP and TCTAP are potent and highly selective antagonists at the μ-opioid receptors mediating presynaptic inhibition of NA release in the brain. The μ-rceeptor affinity of the most potent of these antagonists, TCTOP and TCTAP, appears to be similar to that of naloxone but these antagonists have a much greater selectivity than the latter.
AB - The opioid receptor antagonist properties of four conformaiionally constrained cyclic octapeptidc analogues of somatostatin were investigated using in vitro functional paradigms of μ-, δ- and κ-opioid receptors in the rat brain. The analogues examined were D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP), D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pcn-Thr-NH2 (CTAP), D-Tic-CTOP (TCTOP) and D-Tic-CTAP (TCTAP). Activation of μ-receptors by the enkephalin analogue Tyr-D-Ala-Gly-(NMc)Phc-Gly-ol (DAGO) inhibited the (electrically evoked) release of [3H]noradrenalinc (NA) from superfused cortical slices and this inhibitory effect was antagonized in a competitive fashion by all of the octapeptides tested (pA2 values: CTOP and CTAP 7.9-8.0, TCTOP and TCTAP 8.7-8.8). Selective activation of κ-opioid receptors by the cyclohcxylbenzeneacctamidc U69593 (0.02 μM) inhibited (by 40-45%) the release of [3H]dopamine (DA) from striatal slices, whereas selective activation of δ-opioid receptors by [D-Scr2O-t-butyl),Leu5]enkephalyl-Thr6 (DSTBULET; 0.1 μM) caused an inhibition (by 38-46%) of striatal [14C]acctylcholine (ACh) release. However, these inhibitory effects were not affected by any of the octapeptides in concentrations that caused full antagonism of the inhibitory effect (55-65%) of 0.1 μM DAGO on cortical [3H]NA release. Thus, the cyclic octapcptide somatostatin analogues CTOP, CTAP, TCTOP and TCTAP are potent and highly selective antagonists at the μ-opioid receptors mediating presynaptic inhibition of NA release in the brain. The μ-rceeptor affinity of the most potent of these antagonists, TCTOP and TCTAP, appears to be similar to that of naloxone but these antagonists have a much greater selectivity than the latter.
KW - Neurotransmitter release
KW - Opioid receptor antagonists
KW - Opioid receptors
KW - Presynaptic inhibition
KW - Somatostatin analogues
UR - http://www.scopus.com/inward/record.url?scp=0026009097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026009097&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(91)90761-E
DO - 10.1016/0014-2999(91)90761-E
M3 - Article
C2 - 1687463
AN - SCOPUS:0026009097
SN - 0014-2999
VL - 205
SP - 1
EP - 6
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1
ER -